Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about CYP46A1 overexpression: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| amyloid-beta reduction | causes | phenotype | 0.70 |
| Alzheimer's disease | therapeutic_target_for | disease | 0.70 |
| Huntington's disease | therapeutic_target_for | disease | 0.70 |
| memory restoration | causes | phenotype | 0.70 |
| LXR signaling | activates | pathway | 0.70 |
| SREBP signaling | modulates | pathway | 0.70 |
| lipid raft composition | remodels | mechanism | 0.70 |
| memory function | restores | phenotype | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| CYP46A1 Overexpression Gene Therapy | 0.730 | neurodegeneration | Lipid raft composition changes in synapt |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.852
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Metal Ion Homeostasis Dysregulation in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Wilson Disease Neurodegeneration: Mechanism and Therapeutic Response | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| TREM2, microglia, and Alzheimer's disease. [PMID:33516818] | Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang | Mech Ageing Dev | 2021 | 1 |
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548] | Hong S, Beja-Glasser VF, Nfonoyim BM, Fr | Science | 2016 | 1 |
| Potential Biological Processes Related to Brain SLC13A5 Across the Lifespan: Wei [PMID:41750164] | Ferreira BK, Schuck PF, Ferreira GC, Fre | Brain sciences | 2026 | 0 |
| How cytochrome P450 enzymes in humans are involved in Parkinson's disease: a lit [PMID:41730497] | Ren B, Yan H, Han C, Sun S, Wang D, Xu Y | Neuroscience | 2026 | 0 |
| Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol [PMID:41828569] | Tapia PJ, Rivera BI, Espinoza CS, Stolze | International journal of molec | 2026 | 0 |
| Efavirenz treatment improves retinal vaso-obliteration and pathological neovascu [PMID:41810243] | Bailey B, Rudd Zhong Manis J, Seth G, Ra | Frontiers in medicine | 2026 | 0 |
| Radiosynthesis and Evaluation of 18F‑Labeled Deuterated Radioligand for Positron [PMID:41704371] | Li Y, Song Z, Shi H, Zhao T, Chen J, Zho | ACS medicinal chemistry letter | 2026 | 0 |
| Streptozotocin and L-Buthionine-Sulfoximine Decrease Neuron Membrane Lipid Packi [PMID:40439741] | Martins YA, Cardinali CAEF, Costa AP, To | Neurotoxicity research | 2025 | 0 |
| Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model b [PMID:40540390] | ["Ali T", "Cashion J", "Hannaoui S", "Ah | JCI insight | 2025 | 0 |
| The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] | Dai L, Wang J, Meng L, Zhang X, Xiao T, | PLoS biology | 2025 | 0 |
| Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the [PMID:40045480] | Griffiths L, Hawkins K, Yutuc E, Angelin | Brain pathology (Zurich, Switz | 2025 | 0 |
| Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's dis [PMID:40859407] | Parsai LH, Chali F, Subashi E, Zeitouny | Acta neuropathologica communic | 2025 | 0 |
| Overexpression of cholesterol 24-hydroxylase CYP46A1 attenuates retinal dysfunct [PMID:40975483] | Long Z, Zhang J, Feng J, He T | Experimental eye research | 2025 | 0 |
| Cholesterol metabolic reprogramming mediates microglia-induced chronic neuroinfl [PMID:40987840] | Zhao Q, Li J, Feng J, Wang X, Liu Y, Wan | Nature metabolism | 2025 | 0 |
| Elevated 24-hydroxycholesterol levels counteract okadaic acid-induced tau hyperp [PMID:40653030] | Giannelli S, Eroli F, Loera-Valencia R, | Neurobiology of disease | 2025 | 0 |
| Mesenchymal stem cells overexpressing CYP46A1 inhibit lipopolysaccharide-induced [PMID:40609611] | Shao Y, Ma B, Jin R, Kong N, Tang J, Li | European journal of pharmacolo | 2025 | 0 |
| ABC Transporters, APOE, CYP46A1, and LRP1 Gene Polymorphisms as Markers of Demen [PMID:41226793] | Machowska M, Leszek J, Rączy-Krzemianows | International journal of molec | 2025 | 0 |
| Cholesterol redistribution triggered by CYP46A1 gene therapy improves major hall [PMID:38142760] | Nunes MJ, Carvalho AN, Reis J, Costa D, | Biochimica et biophysica acta. | 2024 | 0 |
| CYP46A1-mediated cholesterol turnover induces sex-specific changes in cognition [PMID:38266095] | Latorre-Leal M, Rodriguez-Rodriguez P, F | Science advances | 2024 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 6 · Score: 0.95 · 2026-04-27
closed · Rounds: 4 · Score: 0.50 · 2026-04-27
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 5 · Score: 0.93 · 2026-04-11
Hypotheses and analyses mentioning CYP46A1 overexpression in their description or question text
No additional research found